MicroRNA-4723 inhibits prostate cancer growth through inactivation of the abelson family of nonreceptor protein tyrosine kinases

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Arora, Sumit ^a   Saini, Sharanjot ^a   Fukuhara, Shinichiro ^a   Majid, Shahana ^a   Shahryari, Varahram ^a   Yamamura, Soichiro ^a   Chiyomaru, Takeshi ^a   Deng, Guoren ^a   Tanaka, Yuichiro ^a   Dahiya, Rajvir ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ABL1 KINASE; ABL2 KINASE; ALPHA3 INTEGRIN; METHYL CPG BINDING PROTEIN; MICRORNA; MICRORNA 4723; TUMOR MARKER; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER DIAGNOSIS; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENICITY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; DOWN REGULATION; ENZYME INACTIVATION; ENZYME REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METASTASIS; MOLECULAR CLONING; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN TARGETING; TUMOR GROWTH; TUMOR INVASION;

APOPTOSIS; BASE SEQUENCE; BINDING SITES; CARCINOGENESIS; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DISEASE PROGRESSION; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; NEOPLASM GRADING; ONCOGENE PROTEINS V-ABL; PROGNOSIS; PROSTATIC NEOPLASMS; RNA INTERFERENCE; TUMOR MARKERS, BIOLOGICAL;

EID: 84891435544     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078023     Document Type: Article

References (49)

1. Ye L, Kynaston HG, Jiang WG (2007) Bone metastasis in prostate cancer: molecular and cellular mechanisms (Review). Int J Mol Med 20: 103-111.
2. Nguyen CT, Kattan MW (2012) Formalized prediction of clinically significant prostate cancer: is it possible? Asian J Androl 14: 349-354.
3. Pendergast AM (2002) The Abl family kinases: mechanisms of regulation and signaling. Adv Cancer Res 85: 51-100.
4. Ganguly SS, Plattner R (2012) Activation of abl family kinases in solid tumors. Genes Cancer 3: 414-425.
5. Colicelli J (2010) ABL tyrosine kinases: evolution of function, regulation, and specificity. Sci Signal 3: re6.
6. Pluk H, Dorey K, Superti-Furga G (2002) Autoinhibition of c-Abl. Cell 108: 247-259.
7. De Braekeleer E, Douet-Guilbert N, Rowe D, Bown N, Morel F, et al. (2011) ABL1 fusion genes in hematological malignancies: a review. Eur J Haematol 86: 361-371.
8. Iijima Y, Ito T, Oikawa T, Eguchi M, Eguchi-Ishimae M, et al. (2000) A new ETV6/TEL partner gene, ARG (ABL-related gene or ABL2), identified in an AML-M3 cell line with a t(1;12)(q25;p13) translocation. Blood 95: 2126-2131.
9. O'Neill AJ, Cotter TG, Russell JM, Gaffney EF (1997) Abl expression in human fetal and adult tissues, tumours, and tumour microvessels. J Pathol 183: 325-329.
10. Singer CF, Hudelist G, Lamm W, Mueller R, Czerwenka K, et al. (2004) Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors. Endocr Relat Cancer 11: 861-869.
11. Lee YC, Huang CF, Murshed M, Chu K, Araujo JC, et al. (2010) Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts. Oncogene 29: 3196-3207.
12. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, et al. (2004) Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47: 6658-6661.
13. Shah NP, Tran C, Lee FY, Chen P, Norris D, et al. (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305: 399-401.
14. Koreckij T, Nguyen H, Brown LG, Yu EY, Vessella RL, et al. (2009) Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br J Cancer 101: 263-268.
15. Yu EY, Massard C, Gross ME, Carducci MA, Culine S, et al. (2011) Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology 77: 1166-1171.
16. Yu EY, Wilding G, Posadas E, Gross M, Culine S, et al. (2009) Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 15: 7421-7428.
17. Rabbani SA, Valentino ML, Arakelian A, Ali S, Boschelli F (2010) SKI-606 (Bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis. Mol Cancer Ther 9: 1147-1157.
18. Iqbal S, Zhang S, Driss A, Liu ZR, Kim HR, et al. (2012) PDGF upregulates Mcl-1 through activation of beta-catenin and HIF-1alpha-dependent signaling in human prostate cancer cells. PLoS One 7: e30764.
19. Balan V, Nangia-Makker P, Kho DH, Wang Y, Raz A (2012) Tyrosinephosphorylated galectin-3 protein is resistant to prostate-specific antigen (PSA) cleavage. J Biol Chem 287: 5192-5198.
20. Teng Y, Ngoka L, Mei Y, Lesoon L, Cowell JK (2012) HSP90 and HSP70 proteins are essential for stabilization and activation of WASF3 metastasispromoting protein. J Biol Chem 287: 10051-10059.
21. Wang Y, Nangia-Makker P, Tait L, Balan V, Hogan V, et al. (2009) Regulation of prostate cancer progression by galectin-3. Am J Pathol 174: 1515-1523.
22. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233.
23. Schickel R, Boyerinas B, Park SM, Peter ME (2008) MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 27: 5959-5974.
24. Ventura A, Jacks T (2009) MicroRNAs and cancer: short RNAs go a long way. Cell 136: 586-591.
25. Hurst DR, Edmonds MD, Welch DR (2009) Metastamir: the field of metastasisregulatory microRNA is spreading. Cancer Res 69: 7495-7498.
26. Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA (2009) MicroRNAs-the micro steering wheel of tumour metastases. Nat Rev Cancer 9: 293-302.
27. Bartels CL, Tsongalis GJ (2009) MicroRNAs: novel biomarkers for human cancer. Clin Chem 55: 623-631.
28. Persson H, Kvist A, Rego N, Staaf J, Vallon-Christersson J, et al. (2011) Identification of new microRNAs in paired normal and tumor breast tissue suggests a dual role for the ERBB2/Her2 gene. Cancer Res 71: 78-86.
29. Wang X (2008) miRDB: a microRNA target prediction and functional annotation database with a wiki interface. RNA 14: 1012-1017.
30. Wang X, El Naqa IM (2008) Prediction of both conserved and nonconserved microRNA targets in animals. Bioinformatics 24: 325-332.
31. Saini S, Majid S, Dahiya R (2010) Diet, microRNAs and prostate cancer. Pharm Res 27: 1014-1026.
32. Bueno MJ, Perez de Castro I, Gomez de Cedron M, Santos J, Calin GA, et al. (2008) Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 13: 496-506.
33. Faber J, Gregory RI, Armstrong SA (2008) Linking miRNA regulation to BCRABL expression: the next dimension. Cancer Cell 13: 467-469.
34. Lopotova T, Zackova M, Klamova H, Moravcova J (2011) MicroRNA-451 in chronic myeloid leukemia: miR-451-BCR-ABL regulatory loop? Leuk Res 35: 974-977.
35. Scholl V, Hassan R, Zalcberg IR (2012) miRNA-451: A putative predictor marker of Imatinib therapy response in chronic myeloid leukemia. Leuk Res 36: 119-121.
36. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, et al. (2008) The impact of microRNAs on protein output. Nature 455: 64-71.
37. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, et al. (2008) Widespread changes in protein synthesis induced by microRNAs. Nature 455: 58-63.
38. Saini S, Arora S, Majid S, Shahryari V, Chen Y, et al. (2011) Curcumin modulates microRNA-203-mediated regulation of the Src-Akt axis in bladder cancer. Cancer Prev Res (Phila) 4: 1698-1709.
39. Saini S, Majid S, Yamamura S, Tabatabai L, Suh SO, et al. (2011) Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis. Clin Cancer Res 17: 5287-5298.
40. Valastyan S, Benaich N, Chang A, Reinhardt F, Weinberg RA (2009) Concomitant suppression of three target genes can explain the impact of a microRNA on metastasis. Genes Dev 23: 2592-2597.
41. Valastyan S, Chang A, Benaich N, Reinhardt F, Weinberg RA (2010) Concurrent suppression of integrin alpha5, radixin, and RhoA phenocopies the effects of miR-31 on metastasis. Cancer Res 70: 5147-5154.
42. Valastyan S, Weinberg RA (2009) MicroRNAs: Crucial multi-tasking components in the complex circuitry of tumor metastasis. Cell Cycle 8: 3506-3512.
43. Clouaire T, Stancheva I (2008) Methyl-CpG binding proteins: specialized transcriptional repressors or structural components of chromatin? Cell Mol Life Sci 65: 1509-1522.
44. Babbio F, Castiglioni I, Cassina C, Gariboldi MB, Pistore C, et al. (2012) Knockdown of methyl CpG-binding protein 2 (MeCP2) causes alterations in cell proliferation and nuclear lamins expression in mammalian cells. BMC Cell Biol 13: 19.
45. Bernard D, Gil J, Dumont P, Rizzo S, Monte D, et al. (2006) The methyl-CpGbinding protein MECP2 is required for prostate cancer cell growth. Oncogene 25: 1358-1366.
46. Yaqinuddin A, Abbas F, Naqvi SZ, Bashir MU, Qazi R, et al. (2008) Silencing of MBD1 and MeCP2 in prostate-cancer-derived PC3 cells produces differential gene expression profiles and cellular phenotypes. Biosci Rep 28: 319-326.
47. Tsuji T (2004) Physiological and pathological roles of alpha3beta1 integrin. J Membr Biol 200: 115-132.
48. Kreidberg JA (2000) Functions of alpha3beta1 integrin. Curr Opin Cell Biol 12: 548-553.
49. Missan DS, Dipersio M (2012) Integrin control of tumor invasion. Crit Rev Eukaryot Gene Expr 22: 309-324.